17 min listen
Uterine Serous Cancers: Advances and Novel Approaches and James Stuart Ferriss
FromIJGC Podcast
ratings:
Length:
35 minutes
Released:
Aug 23, 2021
Format:
Podcast episode
Description
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. James Stuart Ferriss to discuss advances and novel approaches in uterine serous cancers. Dr. Ferriss is an assistant professor in the Kelly Gynecologic Oncology division, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine. He is the program director of the Montz fellowship in gynecologic oncology.
Highlights:
•Uterine serous carcinomas represent less than 10% of all uterine cancers, but 39% of disease specific deaths.
•Surgery remains the cornerstone of treatment.
•Our understanding of the molecular drivers of this uncommon cancer supports new, targeted therapies.
•Adjuvant treatment of advanced and recurrent uterine serous carcinomas should be based on HER2 expression.
• Ongoing clinical trials will further define the role of immunotherapy, WEE1 inhibitors, and PARP inhibitors in uterine serous carcinoma.
Highlights:
•Uterine serous carcinomas represent less than 10% of all uterine cancers, but 39% of disease specific deaths.
•Surgery remains the cornerstone of treatment.
•Our understanding of the molecular drivers of this uncommon cancer supports new, targeted therapies.
•Adjuvant treatment of advanced and recurrent uterine serous carcinomas should be based on HER2 expression.
• Ongoing clinical trials will further define the role of immunotherapy, WEE1 inhibitors, and PARP inhibitors in uterine serous carcinoma.
Released:
Aug 23, 2021
Format:
Podcast episode
Titles in the series (100)
Role of Sentinel Lymph Node Mapping in Cervical Cancer with Michael Frumovitz: In this episode of the IJGC podcast, Editor-in-Ch… by IJGC Podcast